Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)

In a prospective study of AZA pretreatment followed by HSCT in patients with available donor there was a significant improvement in EFS when compared to AZA alone, despite a 19% TRM at 1 year. A significant number of patients dropped off during the AZA pretreatment phase due to progression, death or toxicity; highlighting the need for more effective therapy.

Read the full article here

Related Articles